Trials / Completed
CompletedNCT03047954
Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic Dermatitis
Multicentre, Randomised, Double Blind, Placebo-controlled Study of the Efficacy and Safety of Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 179 (actual)
- Sponsor
- Vifor Pharma · Industry
- Sex
- All
- Age
- 6 Months – 7 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this pilot double-blind study was to evaluate the efficacy and the safety of Broncho-Vaxom 1 capsule (3.5 mg) per day for 9 months compared to placebo on the evolution of the disease in children suffering from Atopic Dermatitis (AD).
Detailed description
Children outpatients of both sexes, aged 6 months to 7 years, with AD confirmed by Haniffin-Rajka or Williams et al, and an AD score (SCORAD) between 25 and 70 were included and followed for 9 months. Patients were randomized to receive either Broncho-Vaxom 1 capsule (3.5 mg) per day or the corresponding placebo over 9 months. Children under general corticotherapy within one month of study start, patients with immunodeficiency, patient's affected body surface area less than 15% or greater than 70% or with known allergy to desonide were excluded. Outcome measures were a comparisons between the two groups in the number of AD flares during the study after the first month of treatment. Secondary outcome measures were comparisons between the two groups based on SCORAD evolution, area of eczema, amount of corticoids used and parents/investigator assessments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Broncho-Vaxom | BV is an orally administered immunostimulating preparation, which consists of a lyophilised bacterial extract prepared from 8 bacterial species (Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae and ozaenae, Staphylococcus aureus, Streptococcus pyogenes and viridans, Neisseria catarrhalis) |
| DRUG | Placebo - Cap | Matching Placebo capsule administered |
Timeline
- Start date
- 2003-07-01
- Primary completion
- 2006-12-01
- Completion
- 2006-12-01
- First posted
- 2017-02-09
- Last updated
- 2017-02-09
Source: ClinicalTrials.gov record NCT03047954. Inclusion in this directory is not an endorsement.